Younes, A., Connors, J. M., Park, S. I., Fanale, M., O'Meara, M. M., Hunder, N. N., . . . Ansell, S. M. (2013). Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. The lancet oncology, 14(13), 1348-1356. https://doi.org/10.1016/S1470-2045(13)70501-1
Citace podle Chicago (17th ed.)Younes, Anas, Joseph M. Connors, Steven I. Park, Michelle Fanale, Megan M. O'Meara, Naomi N. Hunder, Dirk Huebner, a Stephen M. Ansell. "Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Hodgkin's Lymphoma: A Phase 1, Open-label, Dose-escalation Study." The Lancet Oncology 14, no. 13 (2013): 1348-1356. https://doi.org/10.1016/S1470-2045(13)70501-1.
Citace podle MLA (9th ed.)Younes, Anas, et al. "Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Hodgkin's Lymphoma: A Phase 1, Open-label, Dose-escalation Study." The Lancet Oncology, vol. 14, no. 13, 2013, pp. 1348-1356, https://doi.org/10.1016/S1470-2045(13)70501-1.